Cleared Traditional

MENSINK-GOOSEN CATHETER (K844889) - FDA 510(k) Clearance

Class I General & Plastic Surgery device.

K844889 · Goosen Enterprises, Inc. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1985
Decision
91d
Days
Class 1
Risk

K844889 is an FDA 510(k) clearance for the MENSINK-GOOSEN CATHETER. Classified as Catheter, Multiple Lumen (product code GBP), Class I - General Controls.

Submitted by Goosen Enterprises, Inc. (Goldenrod, US). The FDA issued a Cleared decision on March 18, 1985 after a review of 91 days - within the typical 510(k) review window.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4200 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.

View all Goosen Enterprises, Inc. devices

Submission Details

510(k) Number K844889 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 17, 1984
Decision Date March 18, 1985
Days to Decision 91 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
24d faster than avg
Panel avg: 115d · This submission: 91d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GBP Catheter, Multiple Lumen
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4200
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.